Abbott Provides Update on Multi-Drug Resistant TB Test for Centralized Labs | GenomeWeb

NEW YORK (GenomeWeb) – Abbott Diagnostics has recently completed a study in South Africa of its CE-marked multi-drug resistant tuberculosis test, the first on the market to identify resistance to both rifampin and isoniazid.

The study found that the assay, which runs on the firm's automated m2000 RealTime System qPCR platform, is at least as sensitive as current commercial molecular tests designed for decentralized testing, such as Cepheid's GeneXpert MTB/RIF.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.